EMEA-001072-PIP01-10-M04 - paediatric investigation plan
alemtuzumab
PIPHuman
Genzyme Europe B.V.
Tel: +49 (0) 800 52 52 010
E-mail: medinfo.de@sanofi.com
P/0269/2020 : EMA decision of 17 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for alemtuzumab (Lemtrada) (EMEA-001072-PIP01-10-M04)